[Clinical evaluation of 2-(beta-pyridyl-(2")-ethenyl)-3-(2'-methylphenyl)-quinazolinone-(4) (B169) in the treatment of epilepsy].
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004569:Electroencephalography; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004832:Epilepsy, Absence / Q000188:drug therapy; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy; D005030:Ethylenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008607:Intellectual Disability / Q000150:complications; D008297:Male; D009069:Movement Disorders / Q000139:chemically induced; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects
D005030:Ethylenes; D011725:Pyridines; D011799:Quinazolines